Clinical Trial Update: An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating urelumab with nivolumab in advanced solid tumors and advanced B-cell non-Hodgkin's lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Solid Tumors

Drugs mentioned

• Urelumab (urelumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Advanced Solid Tumors, Advanced B-cell NHL | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-10-05